Nathaniel R Smilowitz1, Nipun Bhandari2, Jeffrey S Berger3. 1. Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY, USA; Division of Cardiology, Department of Medicine, Veterans Affairs New York Harbor Health Care System, New York, NY, USA. Electronic address: nathaniel.smilowitz@nyulangone.org. 2. Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY, USA. 3. Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY, USA; Department of Surgery, New York University School of Medicine, New York, NY, USA.
Abstract
BACKGROUND & AIMS: Renal disease is a risk factor for peripheral artery disease (PAD), yet its impact on outcomes after lower extremity (LE) revascularization is not well established. We aimed to characterize the association between chronic kidney disease (CKD) and/or end stage renal disease (ESRD) and post-procedural outcomes in PAD patients undergoing LE revascularization in the United States. METHODS: Adults age ≥18 years undergoing surgical or endovascular LE revascularization for PAD with and without CKD or ESRD were identified from the 2014 Nationwide Readmissions Database. Major adverse cardiovascular events (MACE), defined as a composite of death, myocardial infarction or ischemic stroke, were identified for patients with and without renal disease. All-cause hospital readmissions within 6 months of discharge were determined for all survivors. RESULTS: Among 39,441 patients with PAD hospitalized for LE revascularization, 10,530 had renal disease (26.7%), of whom 69% had CKD without ESRD and 31% had ESRD. Patients with renal disease were more likely to have MACE after LE revascularization (5.2% vs. 2.5%; adjusted OR [aOR] 1.74, 95% CI 1.40-2.16), require LE amputation (26.1% vs. 12.2%; aOR 1.33, 95% CI 1.19-1.50), and require hospital readmission within 6 months (61.0% vs. 43.6%; adjusted HR [aHR] 1.38, 95% CI 1.28-1.48) compared to those without renal disease. CONCLUSIONS: Renal disease is common among patients undergoing LE revascularization for PAD and was independently associated with in-hospital MACE, LE amputation, and hospital readmission within 6 months. Additional efforts to improve outcomes of patients with renal disease and PAD requiring LE revascularization are necessary. Published by Elsevier B.V.
BACKGROUND & AIMS:Renal disease is a risk factor for peripheral artery disease (PAD), yet its impact on outcomes after lower extremity (LE) revascularization is not well established. We aimed to characterize the association between chronic kidney disease (CKD) and/or end stage renal disease (ESRD) and post-procedural outcomes in PADpatients undergoing LE revascularization in the United States. METHODS: Adults age ≥18 years undergoing surgical or endovascular LE revascularization for PAD with and without CKD or ESRD were identified from the 2014 Nationwide Readmissions Database. Major adverse cardiovascular events (MACE), defined as a composite of death, myocardial infarction or ischemic stroke, were identified for patients with and without renal disease. All-cause hospital readmissions within 6 months of discharge were determined for all survivors. RESULTS: Among 39,441 patients with PAD hospitalized for LE revascularization, 10,530 had renal disease (26.7%), of whom 69% had CKD without ESRD and 31% had ESRD. Patients with renal disease were more likely to have MACE after LE revascularization (5.2% vs. 2.5%; adjusted OR [aOR] 1.74, 95% CI 1.40-2.16), require LE amputation (26.1% vs. 12.2%; aOR 1.33, 95% CI 1.19-1.50), and require hospital readmission within 6 months (61.0% vs. 43.6%; adjusted HR [aHR] 1.38, 95% CI 1.28-1.48) compared to those without renal disease. CONCLUSIONS:Renal disease is common among patients undergoing LE revascularization for PAD and was independently associated with in-hospital MACE, LE amputation, and hospital readmission within 6 months. Additional efforts to improve outcomes of patients with renal disease and PAD requiring LE revascularization are necessary. Published by Elsevier B.V.
Authors: Geoffrey R Nunns; Ernest E Moore; Michael P Chapman; Hunter B Moore; Gregory R Stettler; Erik Peltz; Clay C Burlew; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: Am J Surg Date: 2017-09-18 Impact factor: 2.565
Authors: Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh Journal: J Am Coll Cardiol Date: 2017-03-21 Impact factor: 24.094
Authors: Tanush Gupta; Dhaval Kolte; Sahil Khera; Kashish Goel; Wilbert S Aronow; Howard A Cooper; Diwakar Jain; Charanjit S Rihal; Gregg C Fonarow; Julio A Panza; Deepak L Bhatt Journal: JAMA Cardiol Date: 2017-03-01 Impact factor: 14.676
Authors: Paul P Heideman; Mohammad Reza Rajebi; Michael A McKusick; Haraldur Bjarnason; Gustavo S Oderich; Jeremy L Friese; Mark D Fleming; Andrew H Stockland; William S Harmsen; Jay Mandrekar; Sanjay Misra Journal: J Vasc Interv Radiol Date: 2016-06-16 Impact factor: 3.464
Authors: Victor Aboyans; Jean-Baptiste Ricco; Marie-Louise E L Bartelink; Martin Björck; Marianne Brodmann; Tina Cohnert; Jean-Philippe Collet; Martin Czerny; Marco De Carlo; Sebastian Debus; Christine Espinola-Klein; Thomas Kahan; Serge Kownator; Lucia Mazzolai; A Ross Naylor; Marco Roffi; Joachim Röther; Muriel Sprynger; Michal Tendera; Gunnar Tepe; Maarit Venermo; Charalambos Vlachopoulos; Ileana Desormais Journal: Eur Heart J Date: 2018-03-01 Impact factor: 29.983
Authors: Sonia S Anand; Francois Caron; John W Eikelboom; Jackie Bosch; Leanne Dyal; Victor Aboyans; Maria Teresa Abola; Kelley R H Branch; Katalin Keltai; Deepak L Bhatt; Peter Verhamme; Keith A A Fox; Nancy Cook-Bruns; Vivian Lanius; Stuart J Connolly; Salim Yusuf Journal: J Am Coll Cardiol Date: 2018-03-11 Impact factor: 24.094
Authors: Rennier A Martinez; Michelle Shnayder; Joshua Parreco; Lukas Gaffney; Marcus Eby; Nicholas Cortolillo; Michael Lopez; Jack Zeltzer Journal: Ann Vasc Surg Date: 2018-05-17 Impact factor: 1.466
Authors: Clemens Höbaus; Martin Ursli; Sarah Mohammed Yussef; Thomas Wrba; Renate Koppensteiner; Gerit-Holger Schernthaner Journal: Vasc Med Date: 2021-01-15 Impact factor: 3.239
Authors: Artur Kotov; Deven A Blasche; Frederik Peters; Philip Pospiech; Ulrich Rother; Konstantinos Stavroulakis; Jürgen Remig; Christian Schmidt-Lauber; Thomas Zeller; Hartmut Görtz; Jörg Teßarek; Christian-Alexander Behrendt Journal: J Clin Med Date: 2022-08-14 Impact factor: 4.964
Authors: Nam Yong Cho; Russyan Mark Mabeza; Cory Lee; Arjun Verma; Josef Madrigal; Joseph Hadaya; Christian de Virgilio; Peyman Benharash Journal: Surg Open Sci Date: 2022-05-11